Business
QScreen AI Appoints Former Union Pacific Vice President as Strategic Advisor to Drive Expansion into North American Rail and Transportation Markets
Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from a camera without requiring blood, breath, or urine testing.Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today announces the appointment of José Humberto "Beto"...
About this update from Qscreen Ai Inc.
[{"type":"text","content":"Veteran rail executive with 25 years of senior commercial relationships across North America's Class I railroads joins a platform that enables real-time identification of probable drug use from a camera without requiring blood, breath, or urine testing.","length":257,"tagName":"p"},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today announces the appointment of José Humberto "Beto" Vargas García as Strategic Advisor. Mr. Vargas spent over 25 years in senior commercial roles across North American rail and most recently as Vice President at Union Pacific, leading a commercial portfolio of USD$2.8 billion with average annual growth of 9%, where he sat on the Board of Directors of Ferromex and chaired its Operations Committee. He was introduced to the Company during the Canada-Mexico trade mission earlier this year. The Company also announces a change of auditor, described below.","length":755,"tagName":"p"},{"type":"text","content":"The Problem Mr. Vargas Is Here to Solve","length":39,"tagName":"p"},{"type":"text","content":"Every Class I railroad in North America runs mandatory drug and alcohol testing under Federal Railroad Administration regulations. The testing has one fundamental problem: it detects past use, not present impairment. Their legal teams know this and it has been an issue in the industry since cannabis legalization. The Drug Screening Market size was valued at USD $9.76 billion in 2025 and is likely to cross USD $40.18 billion by 2035, expanding at more than 15.2% CAGR during the forecast period. In the year 2026 itself, the industry size of drug screening is assessed at USD $11.1 billion.1","length":594,"tagName":"p"},{"type":"text","content":"The QAI Platform reads physiological signals from a standard camera including PERCLOS, blink rate, head movement, pupil reactivity and identifies the probable substance a person has consumed in real time. No sample required and therefore no lab visit and no wait times. The system generates a documented, time-stamped output before each shift begins, directly meeting the requirements of the transportation industry.","length":416,"tagName":"p"},{"type":"text","content":"Mr. Vargas has deep relationsh...